NeuroSense Therapeutics announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease (AD).
NeuroSense Therapeutics announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease (AD).
© NeuroSense Therapeutics 2021 All Rights Reserved | Site by: Webnoise | Privacy Policy | Terms | Accessibility